Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Pureos Bioventures

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 15
Average round size
The average size of a deal this fund participated in
Portfolio companies 13
Lead investments 3
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 1
Key employees 3
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Therapeutics
  • Health Care
  • Medical
  • Life Science

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Pureos Bioventures, startups are often financed by Ysios Capital, Kurma Partners, BB Biotech Ventures. The meaningful sponsors for the fund in investment in the same round are Bpifrance, Ysios Capital, Quark Venture.

The common things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2019. The fund is generally included in 2-6 deals every year. Speaking about the real fund results, this VC is 47 percentage points more often commits exit comparing to other organizations.

The fund has no exact preference in some founders of portfolio startups. Among the most popular fund investment industries, there are Pharmaceutical, Biotechnology. Besides, a startup requires to be at the age of 11-15 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight AM Pharma, NovaGo Therapeutics.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Pureos Bioventures:
Typical Co-investors
Pureos Bioventures is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Pureos Bioventures:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from Switzerland
Funds with similar focus located in Switzerland:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Bow Capital California, Menlo Park, United States
Carbon Black Massachusetts, United States, Waltham
Changjiang Fund China, Hubei, Wuhan
Efficient Capacity fund California, San Francisco, United States
Elite Capital China, Shanghai
F&G Venture China, Shanghai, Shanghai
Flipkart Bengaluru, India, Karnataka
Genesis Capital Ventures Guadalajara, Jalisco, Mexico
Guangzhou Municipal Government China, Guangdong, Guangzhou
I2 Technologies Dallas, Texas, United States
Iberdrola Bilbao, Pais Vasco, Spain
Juxin Ziben China, Hangzhou, Zhejiang
Mingyao Guquan Touzi China, Shanghai
Sony Pictures Television California, Culver City, United States
SP Investment Fund California, Santa Monica, United States
Stobart Group England, Germany, Nordrhein-Westfalen
Tao Tsuot HaMerkaz, Israel, Petah Tiqva
Ventureworks India India, Maharashtra, Mumbai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

ImCheck Therapeutics

Health Care
Life Science
$113M13 Jun 2022 Marseille, Provence-Alpes-Côte d'Azur, France

Ariceum Therapeutics

Health Care
$29M08 Jun 2022 Berlin, Berlin, Germany

Engimmune Therapeutics

$16M03 May 2022 Basel, Basel-Stadt, Switzerland

Acrivon Therapeutics

Health Care
$100M11 Nov 2021 Cambridge, Massachusetts, United States

Alentis Therapeutics

$65M15 Jun 2021 Basel, Basel-City, Switzerland

Hummingbird Bioscience

Health Care
$125M18 May 2021 Singapore, Central Region, Singapore

Corlieve Therapeutics

02 Nov 2020 Ile-de-France

Araris Biotech

$16M22 Oct 2020 Zurich, Zurich, Switzerland

Lava Therapeutics

Life Science
Medical Device
$83M17 Sep 2020 Utrecht, Utrecht, Netherlands
Hummingbird Bioscience Raises US$125M in Series C Financing

– Hummingbird Bioscience from Singapore develops precision therapies against hard-to-drug targets to improve treatment outcomes.
– Series C $125m round brings company valuation to more than $1b.
– The round was led by Novo Holdings with participation from new investors – Frazier Healthcare Partners, Octagon Capital, EDBI, AMGEN Ventures, DROIA Ventures, Morningside Ventures, Pureos Bioventures, Polaris Partners, Affinity Asset Advisors, Ally Bridge Group and Altrium Capital Management and existing investors SK Inc, Heritas Capital, and Mirae Asset Venture Capital.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Pureos Bioventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: